Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$65.41
-1.3%
$62.88
$52.50
$77.00
$1.44B0.57320,827 shs347,030 shs
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
$36.93
+1.7%
$33.35
$23.15
$40.88
$1.82B0.77338,034 shs232,480 shs
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$3.65
$3.65
$2.76
$6.65
$381.02M0.93.76 million shsN/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$22.82
+6.4%
$21.94
$16.60
$28.47
$1.57B1.58927,581 shs1.64 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-1.34%+0.34%-0.23%-5.13%+5.18%
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
+1.71%+4.62%+17.84%+25.10%-7.16%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
0.00%0.00%0.00%0.00%+0.41%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
+6.39%+7.95%+11.53%-12.20%+6.79%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
3.8643 of 5 stars
2.51.00.03.33.23.31.3
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
1.0513 of 5 stars
3.30.00.00.00.02.50.0
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
2.7176 of 5 stars
3.10.00.04.70.01.70.6
Schrodinger, Inc. stock logo
SDGR
Schrodinger
2.062 of 5 stars
3.41.00.00.02.51.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
3.00
Buy$78.8820.59% Upside
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
2.55
Moderate Buy$58.8959.46% Upside
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
2.13
Hold$8.45131.51% Upside
Schrodinger, Inc. stock logo
SDGR
Schrodinger
2.75
Moderate Buy$32.7543.51% Upside

Current Analyst Ratings Breakdown

Latest RVNC, IMCR, ANIP, and SDGR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/14/2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$32.00 ➝ $30.00
7/10/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$84.00
7/3/2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight$28.00
6/2/2025
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$100.00
5/27/2025
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$65.00
5/12/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$86.00 ➝ $86.00
5/8/2025
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.00
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$614.38M2.31$7.49 per share8.73$19.11 per share3.42
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
$310.20M5.98N/AN/A$7.20 per share5.13
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$234.04M1.63N/AN/A($1.73) per share-2.11
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$207.54M8.07N/AN/A$5.78 per share3.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-$18.52M-$1.27N/A15.54N/A-3.12%21.35%7.52%8/5/2025 (Estimated)
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
-$51.09M-$0.43N/AN/AN/A-6.48%-5.86%-2.09%8/6/2025 (Estimated)
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%8/6/2025 (Estimated)
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$187.12M-$2.63N/AN/AN/A-83.39%-44.74%-26.29%7/30/2025 (Estimated)

Latest RVNC, IMCR, ANIP, and SDGR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
-$0.21N/AN/AN/AN/AN/A
8/5/2025Q2 2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$1.49N/AN/AN/A$187.18 millionN/A
7/30/2025Q2 2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$0.83N/AN/AN/A$52.03 millionN/A
5/9/2025Q1 2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$1.37$1.70+$0.33$0.69$179.75 million$197.12 million
5/7/2025Q1 2025
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million
5/7/2025Q1 2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
N/AN/AN/AN/AN/A
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
N/AN/AN/AN/AN/A
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
N/AN/AN/AN/AN/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
1.46
2.66
1.98
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
1.03
6.36
6.31
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
N/A
4.12
3.05
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/A
3.45
3.45

Institutional Ownership

CompanyInstitutional Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
76.05%
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
84.50%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
97.70%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79.05%

Insider Ownership

CompanyInsider Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
12.70%
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
10.40%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
5.10%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
8.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
60021.66 million18.91 millionOptionable
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
32050.23 million45.01 millionOptionable
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
500104.39 million99.07 millionOptionable
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79073.38 million67.07 millionOptionable

Recent News About These Companies

Schrodinger (NASDAQ:SDGR) Stock Price Up 8.6% - Here's Why
Comparing Schrodinger (NASDAQ:SDGR) & Strata Skin Sciences (NASDAQ:SSKN)
BMO Capital Remains a Buy on Schrodinger (SDGR)
Schrödinger, Inc. (SDGR) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANI Pharmaceuticals stock logo

ANI Pharmaceuticals NASDAQ:ANIP

$65.41 -0.89 (-1.34%)
Closing price 07/21/2025 04:00 PM Eastern
Extended Trading
$65.50 +0.09 (+0.15%)
As of 07/21/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Immunocore stock logo

Immunocore NASDAQ:IMCR

$36.93 +0.62 (+1.71%)
Closing price 07/21/2025 04:00 PM Eastern
Extended Trading
$36.92 -0.02 (-0.04%)
As of 07/21/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Revance Therapeutics stock logo

Revance Therapeutics NASDAQ:RVNC

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Schrodinger stock logo

Schrodinger NASDAQ:SDGR

$22.82 +1.37 (+6.39%)
Closing price 07/21/2025 04:00 PM Eastern
Extended Trading
$22.95 +0.13 (+0.57%)
As of 09:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.